|Dr. Hans-George Feldmeier||CEO & Chairman of the Management Board||N/A||N/A||N/A|
|Ms. Hilde Neumeyer||CFO, Chief Compliance Officer & Member of the Management Board||N/A||N/A||N/A|
|Ms. Karin Samusch||Member of the Management Board & Chief Bus. Devel. Officer||N/A||N/A||N/A|
|Dr. JÃ¼rgen Ott||Chief Marketing Officer & Member of Management Board||N/A||N/A||1969|
Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three divisions: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, enzymes, dermatologics, systemic corticoids, women's healthcare, pain treatment, and ophthalmologics primarily under the Dekristol, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; food supplements under the HÃ¼bner brand; and Azedil, a nasal spray and eye drop product to treat acute hay fever symptoms. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. Dermapharm Holding SE has partnership with CORAT Therapeutics GmbH for the development of COR-101. The company was founded in 1991 and is headquartered in GrÃ¼nwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
Dermapharm Holding SE’s ISS Governance QualityScore as of July 1, 2021 is 10. The pillar scores are Audit: 7; Board: 10; Shareholder Rights: 1; Compensation: 6.